Do Not Do Recommendation

 
Bevacizumab, sorafenib and temsirolimus are not recommended as first-line treatment options for people with advanced and/or metastatic renal cell carcinoma.

Do Not Do Recommendation Details

Recommendation:
Bevacizumab, sorafenib and temsirolimus are not recommended as first-line treatment options for people with advanced and/or metastatic renal cell carcinoma.
Interventions:
bevacizumab; sorafenib; temsirolimus

Source guidance details

Guidance:
Renal cell carcinoma (TA178)
Published date:
August 2009
Paragraph number:
1.1
Page number:
4

View all NICE do not do from this Guidance